World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
32558
World Ranking
11271
National Ranking
5786

Matthew H. Kulke publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Matthew H. Kulke sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 393 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Matthew H. Kulke D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Matthew H. Kulke sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Matthew H. Kulke is affiliated with Boston Medical Center in the United States. Their research primarily focuses on medicine, with a significant concentration in oncology. Within this field, they have contributed extensively to subfields such as oncology, epidemiology, neurology, pulmonary and respiratory medicine, and molecular biology.

Their research topics cover a range of cancer-related studies, including neuroendocrine tumor research advances, lung cancer research studies, neuroblastoma research and treatments, pancreatic and hepatic oncology research, lung cancer treatments and mutations, colorectal cancer treatments and studies, and gestational trophoblastic disease studies.

Kulke has authored several recent publications, including:

  • PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023), published in Molecular Cancer
  • Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) (2022), published in Journal of Clinical Oncology
  • Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020), published in European Journal of Nuclear Medicine and Molecular Imaging
  • Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (2024), published in New England Journal of Medicine
  • Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions (2021), published in Clinical Cancer Research

Frequent collaborators in their research include:

  • Jonathan Strosberg
  • Jennifer A. Chan
  • Lauren K. Brais
  • James C. Yao
  • Kimberly Perez

The main venues where their work is published include:

  • Journal of Clinical Oncology
  • Pancreas
  • The Oncologist
  • UNC Libraries
  • Clinical Cancer Research

Best Publications

  • Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

    Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar

  • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni

  • Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

    James C. Yao;Catherine Lombard-Bohas;Eric Baudin;Larry K. Kvols

  • Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

    Matthew H. Kulke;Heinz Josef Lenz;Neal J. Meropol;James Posey

  • NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

    Matthew H. Kulke;Lowell B. Anthony;David L. Bushnell;Wouter W. de Herder

  • Consensus guidelines for the management and treatment of neuroendocrine tumors.

    Pamela L. Kunz;Diane Reidy-Lagunes;Lowell B. Anthony;Erin M. Bertino

  • Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

    Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan

  • Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.

    Jin Li;Lilin Wang;Harvey Mamon;Matthew H Kulke

  • Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

    Matthew B. Yurgelun;Matthew H. Kulke;Charles S. Fuchs;Brian A. Allen

  • Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set

    David S. Klimstra;Irvin R. Modlin;N. Volkan Adsay;Runjan Chetty

  • O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

    Matthew H. Kulke;Jason L. Hornick;Christine Frauenhoffer;Susanne Hooshmand

  • Passive Stiffness Changes Caused by Upregulation of Compliant Titin Isoforms in Human Dilated Cardiomyopathy Hearts

    I. Makarenko;C.A. Opitz;M.C. Leake;C. Neagoe

  • Neuroendocrine tumors, version 1.2015

    Matthew H. Kulke;Manisha H. Shah;Al B. Benson;Emily Bergsland

  • The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (High-Grade) extrapulmonary neuroendocrine carcinomas

    Jonathan R. Strosberg;Domenico Coppola;David S. Klimstra;Alexandria T. Phan

  • Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

    J Souglakos;J Philips;R Wang;S Marwah

  • NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.

    Clark Oh;Benson Ab rd;Berlin Jd;Choti Ma

  • Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

    Matthew H. Kulke;Lillian L. Siu;Joel E. Tepper;George Fisher

  • Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

    Brian M. Wolpin;Cosmeri Rizzato;Peter Kraft;Charles Kooperberg

  • Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

    Joshua M Francis;Joshua M Francis;Adam Kiezun;Alex H Ramos;Alex H Ramos;Stefano Serra

  • Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

    Jonathan Strosberg;Edward Wolin;Beth Chasen;Matthew Kulke

Frequent Co-Authors

Kjell Öberg
Kjell Öberg Uppsala University
James C. Yao
James C. Yao The University of Texas MD Anderson Cancer Center
Jennifer A. Chan
Jennifer A. Chan University of Calgary
David C. Christiani
David C. Christiani Harvard University
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
David P. Ryan
David P. Ryan Harvard University
Juan W. Valle
Juan W. Valle University of Manchester
Jeffrey W. Clark
Jeffrey W. Clark Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in the medical field but unsure about committing to medical school, there are several related online degrees and alternative career pathways to consider. Many students choose direct admit nursing programs for a streamlined path into nursing, often bypassing the competitive re-application process seen in traditional tracks.

For those seeking flexible study options, online medical coding classes with financial aid can provide affordable ways to enter the growing field of medical billing and coding. Additionally, some nursing schools now offer absn programs that don't require teas, making advanced nursing degrees more accessible for students worried about entrance exams.

If you are interested in the business and administrative side of healthcare, consider a health care administration degree online. These programs prepare you for leadership roles and can usually be completed while working.

Exploring these diverse online programs can help you find the right fit for your career ambitions—whether your goal is direct patient care, medical office support, or healthcare management.

Best Scientists Citing Matthew H. Kulke

Trending Scientists

Recently Published Articles